180 Life Sciences Corp. (ATNF)

NASDAQ: ATNF · IEX Real-Time Price · USD
1.740
+0.070 (4.19%)
May 24, 2024, 10:10 AM EDT - Market open
4.19%
Market Cap 1.63M
Revenue (ttm) n/a
Net Income (ttm) -16.24M
Shares Out 941.59K
EPS (ttm) -29.19
PE Ratio n/a
Forward PE 6.08
Dividend n/a
Ex-Dividend Date n/a
Volume 17,889
Open 1.730
Previous Close 1.670
Day's Range 1.620 - 1.780
52-Week Range 1.330 - 26.030
Beta 0.43
Analysts n/a
Price Target n/a
Earnings Date May 15, 2024

About ATNF

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ATNF
Full Company Profile

Financial Performance

Financial Statements

News

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 202...

2 months ago - GlobeNewsWire

180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan

PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its ou...

3 months ago - GlobeNewsWire

180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives

PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as fi...

6 months ago - GlobeNewsWire

180 Life Sciences Announces Review of Strategic Alternatives

PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process ...

6 months ago - GlobeNewsWire

180 Life Sciences Corp. Announces Closing of $3 Million Public Offering

PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing o...

10 months ago - GlobeNewsWire

180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering

PALO ALTO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the pricing o...

10 months ago - GlobeNewsWire

180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that an agreement has been reached with Prof. Avi Do...

10 months ago - GlobeNewsWire

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

PALO ALTO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing ...

1 year ago - GlobeNewsWire

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

Priced At-The-Market Under Nasdaq Rules Priced At-The-Market Under Nasdaq Rules

1 year ago - GlobeNewsWire

180 Life Sciences Announces Presentation at the Gordon Conference

PALO ALTO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that Professor Jagdeep Nanchahal has been selected t...

1 year ago - GlobeNewsWire

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren's Disease Treatment and Application

PALO ALTO, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the United States Patent and Trademark Office (...

1 year ago - GlobeNewsWire

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

PALO ALTO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced closure to recruitment of men and women across Engla...

1 year ago - GlobeNewsWire

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease

PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for...

1 year ago - GlobeNewsWire

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that it has an ongoing investigation into actions taken by officers and directors of KBL Merger Corp. IV (“KBL”), a special purpose acqu...

1 year ago - Business Wire

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease

PALO ALTO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Dupuytren's di...

1 year ago - GlobeNewsWire

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

PALO ALTO, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Dear Fellow Shareholder,

1 year ago - GlobeNewsWire

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PALO ALTO, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing o...

1 year ago - GlobeNewsWire

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PALO ALTO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) --  180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that it has ...

1 year ago - GlobeNewsWire

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

PALO ALTO, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will effect a one-for-20 reverse stock split...

1 year ago - GlobeNewsWire

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture

PALO ALTO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company and its regulatory consultants from...

1 year ago - GlobeNewsWire

180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 – December 1, 2022

PALO ALTO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of...

1 year ago - GlobeNewsWire

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences Corp. An embedded...

1 year ago - GlobeNewsWire

180 Life Sciences Issues Letter to Stockholders

PALO ALTO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today released the following...

1 year ago - GlobeNewsWire

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first pati...

1 year ago - GlobeNewsWire

180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program Wi

PALO ALTO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced that a team ...

1 year ago - GlobeNewsWire